MarketFriction

Colinz Laboratories Ltd

BSE 531210 · Pharmaceuticals
₹73.50 -4.16%
BSE close2026-10-01
Market cap₹9.41 Cr.
P/E18.8

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue from operations1.791.711.631.751.861.471.451.571.391.431.751.24
Operating costs1.671.571.511.591.691.401.351.441.311.331.661.18
EBITDA0.120.140.120.160.170.070.100.130.080.100.090.06
EBITDA margin %6.70%8.19%7.36%9.14%9.14%4.76%6.90%8.28%5.76%6.99%5.14%4.84%
Depreciation & amortisation0.030.030.030.030.030.030.030.040.040.040.040.04
Finance costs0.010.010.010.010.010.010.020.010.010.010.010.01
Non-operating income0.080.050.110.070.080.080.080.080.160.080.172.89
Pre-tax profit0.160.150.190.190.210.110.130.160.190.130.212.90
Effective tax rate %25.00%26.67%31.58%26.32%23.81%45.45%-23.08%25.00%26.32%30.77%19.05%17.24%
Profit after tax0.120.110.140.140.160.050.150.120.140.080.172.40
Earnings per share (Rs)0.480.440.560.560.640.200.600.480.560.320.679.53
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue from operations8.108.057.837.597.536.166.977.157.036.536.145.81
Operating costs7.657.647.487.247.225.826.386.526.496.045.725.48
EBITDA0.450.410.350.350.310.340.590.630.540.490.420.33
EBITDA margin %5.56%5.09%4.47%4.61%4.12%5.52%8.46%8.81%7.68%7.50%6.84%5.68%
Depreciation & amortisation0.280.270.220.220.190.190.200.130.130.130.160.16
Finance costs0.120.120.080.100.070.090.080.050.040.040.050.04
Non-operating income0.100.090.100.120.130.190.170.150.280.300.483.30
Pre-tax profit0.150.110.150.150.180.250.480.600.650.620.693.43
Effective tax rate %40.00%-27.27%-53.33%26.67%27.78%16.00%29.17%23.33%26.15%20.97%24.64%
Profit after tax0.090.140.230.120.130.210.340.460.490.500.512.79
Earnings per share (Rs)0.200.310.500.260.280.460.741.831.951.982.0211.08
Paid out as dividend %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Revenue CAGR-3%0%-5%-9%
Profit CAGR19%19%2%4%
Share price CAGR16%31%22%73%
Average return on equity4%5%5%5%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Net block (property, plant)3.162.882.632.412.212.062.031.861.711.581.701.54
Capital work in progress0.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.290.290.410.530.500.360.610.670.661.021.041.11
Current & other assets7.216.586.646.656.466.397.467.407.868.769.0810.13
Total assets10.669.759.689.599.178.8110.109.9310.2311.3611.8212.78
Share capital3.543.543.543.543.543.543.553.552.522.522.522.52
Reserves & surplus2.622.712.983.213.303.293.754.145.626.436.967.52
Total debt2.531.800.760.420.680.380.990.480.270.570.640.39
Other liabilities & provisions1.971.702.402.421.651.601.811.761.821.841.702.35
Equity + liabilities10.669.759.689.599.178.8110.109.9310.2311.3611.8212.78
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating cash flow0.090.580.060.340.120.582.160.470.401.03-1.452.54
Investing cash flow0.030.00-0.01-0.11-0.01-0.04-0.16-0.030.010.01-0.230.01
Free cash flow (after capex)0.090.580.040.340.120.542.000.430.401.03-1.712.54
Financing cash flow0.45-0.73-0.030.010.020.060.080.090.110.230.240.43
Net change in cash0.57-0.160.020.240.120.602.070.520.521.27-1.452.98
Cash conversion (OCF / EBITDA) %26%136%22%106%43%210%659%105%89%224%-253%650%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Return on capital employed %3.20%3.23%3.00%3.18%3.40%3.39%4.39%6.80%8.08%7.70%6.62%7.20%
Receivable days62.5360.8366.6578.3180.7972.2277.0363.3657.6944.6536.8949.93
Inventory days288.96232.18267.25266.31246.80225.13208.33147.59149.17134.31136.22148.55
Payable days116.2460.6655.6891.9344.1649.2990.0076.17103.1594.8194.3180.64
Cash cycle (days)235.25232.35278.23252.70283.42248.06195.36134.78103.7184.1578.81117.84
Working capital days110.24100.0471.1972.7289.4579.010.009.9511.23-22.8473.22-60.64
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoter group %66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%66.00%50.60%
Retail & others %34.00%34.00%34.00%34.00%34.00%33.99%33.99%34.00%33.99%34.00%34.00%49.39%
Shareholder count2,8732,9152,9292,9803,1163,2023,2163,2383,2723,2123,2503,174

Fundamentals

Market value₹ 9.41 Cr.
Last price₹ 74.7
P/E (trailing)18.8
Book value / share₹ 39.9
Return on capital7.20 %
Return on equity5.23 %
Dividend yield0.00 %
Face value₹ 10.0
Revenue CAGR (TTM)-9%
Profit CAGR (TTM)4%
Standalone figures.
Valuation
Market capRs 19 Cr
Enterprise valueRs 10 Cr
P/E (TTM)6.64x
Price to book1.84x
Price to sales3.19x
EV / EBITDA2.86x
EV / EBIT2.99x
EV / sales1.79x
Price to cash flow7.29x
Earnings yield15.07%
P/E, 3-year average25.93x
P/B, 3-year average1.37x
P/E, 5-year average25.72x
P/B, 5-year average1.32x
Profitability
Operating margin (excl. other income)6.84%
Operating margin (incl. other income)14.66%
EBITDA margin62.48%
Pre-tax margin59.04%
Net profit margin48.02%
Net margin, latest quarter193.55%
ROE5.23%
ROCE7.20%
ROA4.15%
ROE, 3-year average5.46%
ROCE, 3-year average7.21%
ROA, 3-year average4.33%
ROE, 5-year average5.35%
ROCE, 5-year average7.25%
ROA, 5-year average4.19%
ROIC (approx.)137.64%
Tax rate24.64%
Other income / net worth4.78%
Growth
Sales growth (latest year)-5.97%
Profit growth (latest year)2.00%
Sales CAGR, 3 years-4.95%
Sales CAGR, 5 years-0.07%
Profit CAGR, 3 years3.50%
Profit CAGR, 5 years19.42%
Sales growth QoQ-29.14%
Profit growth QoQ1311.76%
Sales growth YoY (latest quarter)-21.02%
Profit growth YoY (latest quarter)1900.00%
Per share
EPS (TTM)Rs 11.08
EPS (latest year)Rs 2.02
EPS (latest quarter)Rs 9.53
EPS, 3-year averageRs 1.98
EPS, 5-year averageRs 1.70
Book value per shareRs 39.86
Sales per shareRs 23.06
Cash flow per shareRs 10.08
Efficiency
Asset turnover0.48x
Fixed asset turnover3.99x
Inventory turnover2.84x
Inventory days128 days
Debtor days50 days
Debtors turnover7.31x
Leverage
Total debtRs 0 Cr
Cash and bankRs 9 Cr
Net debtRs -8 Cr
Debt to equity0.04x
Net debt / EBITDA-2.24x
Interest coverage86.75x
Owners' fund to total sources78.56%
Debt to assets3.05%
Cash flow
Operating cash flow (latest year)Rs 3 Cr
Investing cash flow (latest year)Rs 0 Cr
Financing cash flow (latest year)Rs 0 Cr
Net change in cash (latest year)Rs 3 Cr
Sales to cash flow2.42x
Statement figures
Net sales (TTM)Rs 6 Cr
Net sales (latest year)Rs 6 Cr
Sales (latest quarter)Rs 1 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 4 Cr
PBDT (TTM)Rs 4 Cr
Profit before tax (TTM)Rs 3 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 3 Cr
Net profit (latest year)Rs 1 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 2 Cr
Total expenditure (latest year)Rs 6 Cr
Total income (latest year)Rs 7 Cr
Share capitalRs 3 Cr
ReservesRs 8 Cr
Shareholders' fundsRs 10 Cr
Total assetsRs 13 Cr
Net blockRs 2 Cr
InvestmentsRs 1 Cr
ReceivablesRs 1 Cr
InventoryRs 1 Cr
Other liabilitiesRs 2 Cr
Shares outstanding (crore)0.25
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 6.6 is at the 1th percentile of its own 9.2-year range (median 22.4, low 6.5, high 41.1).
P/B 1.84 is at the 94th percentile (median 0.95).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period531210Nifty 50Difference
1 week-2.0%-2.8% +0.8 pts
1 month-1.7%-6.8% +5.1 pts
3 months-11.7%-7.6% -4.1 pts
3 years+79.7%+14.2% +65.5 pts
5 years+259.4%+27.9% +231.5 pts

Red flags

F-score 5 of 8
explainReceivables outrunning sales Receivables grew 27% vs sales -6% in 2026
lookProfit leans on other income Other income was 70% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹1 Cr -21.0% vs Jun 2025. Net profit ₹2 Cr +1900.0%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Colinz Laboratories Ltd?

Colinz Laboratories Ltd (531210) has a market capitalisation of Rs 9.41 Cr. at the 2026-10-01 close.

What is the P/E ratio of Colinz Laboratories Ltd?

Colinz Laboratories Ltd trades at a P/E of 18.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Colinz Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Colinz Laboratories Ltd sales was Rs 1 Cr (-21.0% vs Jun 2025) and net profit was Rs 2 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03